A controlled clinical trial of small daily doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy. A Hong Kong Tuberculosis Treatment Services-British Medical Research Council Investigation.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000906:Antibodies / Q000032:analysis; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007565:Jaundice / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D010919:Placebos; D011718:Pyrazinamide / Q000627:therapeutic use; D012140:Respiratory Tract Diseases / Q000139:chemically induced; D012293:Rifampin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D012877:Skin Manifestations; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000906:Antibodies; D010919:Placebos; D011718:Pyrazinamide; D004977:Ethambutol; D000410:Alanine Transaminase; D012293:Rifampin